Next, we examined the expression of MDR markers, specifically ABCB1, ABCC1, and ABCG2, in NSCLC cultures after treatment with afatinib, alectinib, ceritinib, crizotinib, dabrafenib, erlotinib, gefitinib, nintedanib, osimertinib, and trametinib. This evidence concerns the gene ABCC1 and non-small cell lung carcinoma.